Assignee
LEK PHARMACEUTICALS
SI·57 granted patents·43 pending applications·345 citations·filing 1999–2022
Top patents by PatentIndex Score
100 records- 0191US6531507B1Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the sameLEK PHARMACEUTICALS·Filed 2000·Granted Mar 11, 2003·47 cites·26 claims
- 0290US8053444B2Sirolimus formulationLEK PHARMACEUTICALS·Filed 2008·Granted Nov 8, 2011·20 cites·7 claims
- 0389US6583295B1Salts of HMG-CoA reductase inhibitorsLEK PHARMACEUTICALS·Filed 1999·Granted Jun 24, 2003·32 cites·44 claims
- 0488US6613916B2Process for the preparation of amorphous atorvastatinLEK PHARMACEUTICALS·Filed 2000·Granted Sep 2, 2003·30 cites·14 claims
- 0587US7485322B2Modified release pharmaceutical compositionLEK PHARMACEUTICALS·Filed 2003·Granted Feb 3, 2009·29 cites·44 claims
- 0684US6838566B2Salts of HMG-CoA reductase inhibitorsLEK PHARMACEUTICALS·Filed 2002·Granted Jan 4, 2005·10 cites·48 claims
- 0784US6740775B1Crystalline sodium salt of pravastatinLEK PHARMACEUTICALS·Filed 2003·Granted May 25, 2004·15 cites·20 claims
- 0882US7030151B2Atorvastatin calcium in a pharmaceutical form composition thereof and pharmaceutical formulation comprising atorvastatin calciumLEK PHARMACEUTICALS·Filed 2002·Granted Apr 18, 2006·39 cites·18 claims
- 0982US6806290B2Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the sameLEK PHARMACEUTICALS·Filed 2002·Granted Oct 19, 2004·14 cites·43 claims
- 1081US6891047B2Process for the preparation of amorphous atorvastatinLEK PHARMACEUTICALS·Filed 2003·Granted May 10, 2005·14 cites·16 claims
- 1178US9732053B21-[2-(2,4-dimethylphenylsulfanyl) phenyl]piperazine acetate in crystalline formLEK PHARMACEUTICALS·Filed 2014·Granted Aug 15, 2017·2 cites·14 claims
- 1278US9493409B2Process for the synthesis of 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazineLEK PHARMACEUTICALS·Filed 2014·Granted Nov 15, 2016·3 cites·4 claims
- 1378US8354530B2Process for the synthesis of rosuvastatin calciumLEK PHARMACEUTICALS·Filed 2006·Granted Jan 15, 2013·4 cites·16 claims
- 1475US9284320B2Ticagrelor adducts with divalent metal saltsLEK PHARMACEUTICALS·Filed 2013·Granted Mar 15, 2016·2 cites·9 claims
- 1572US7906109B2Pharmaceutical composition comprising an active principal and sulphobetaineLEK PHARMACEUTICALS·Filed 2004·Granted Mar 15, 2011·7 cites·11 claims
- 1672US6984399B2Solid pharmaceutical formulation containing lovastatin and simvastatin respectively, and its preparationLEK PHARMACEUTICALS·Filed 2003·Granted Jan 10, 2006·5 cites·9 claims
- 1771US6696086B1Solid pharmaceutical formulation containing lovastatin and simvastatin, respectively, and its preparationLEK PHARMACEUTICALS·Filed 2000·Granted Feb 24, 2004·5 cites·14 claims
- 1869US9388188B2Synthetic route for the preparation of β-aminobutyryl substituted 5,6,7,8-tetrahydro[1,4]diazolo[4,3-alpha ]pyrazin-7-yl compoundsLEK PHARMACEUTICALS·Filed 2013·Granted Jul 12, 2016·2 cites·11 claims
- 1968US7655437B2Synthetic gene coding for human granulocyte-colony stimulating factor for the expression in E. coliLEK PHARMACEUTICALS·Filed 2003·Granted Feb 2, 2010·9 cites·13 claims
- 2066US6680341B1Stable pharmaceutical formulation comprising a HMG-CoA reductase inhibitorLEK PHARMACEUTICALS·Filed 1999·Granted Jan 20, 2004·19 cites·39 claims
- 2165US9944599B2Processes for the preparation of beta-aminosulfone compoundsLEK PHARMACEUTICALS·Filed 2015·Granted Apr 17, 2018·1 cites·10 claims
- 2265US7141602B2Process for obtaining HMG-CoA reductase inhibitors of high purityLEK PHARMACEUTICALS·Filed 2003·Granted Nov 28, 2006·1 cites·5 claims
- 2364US2011136883A1Granulation of active pharmaceutical ingredientsLEK PHARMACEUTICALS·Filed 2009·Application pending·0 cites
- 2463US2010056605A1Oxidative degradation products of atorvastatin calciumLEK PHARMACEUTICALS·Filed 2009·Application pending·0 cites
- 2563US2024424059A1Formulations for VEGF Receptor Fusion ProteinsLEK PHARMACEUTICALS·Filed 2022·Application pending·0 cites
- 2662US9453030B2Oxidative degradation products of atrovastatin calciumLEK PHARMACEUTICALS·Filed 2014·Granted Sep 27, 2016·0 cites·9 claims
- 2761US7585496B2Stable pharmaceutical composition granulocyte-colony stimulating factorLEK PHARMACEUTICALS·Filed 2003·Granted Sep 8, 2009·2 cites·19 claims
- 2860US2008188552A1New salts of HMG-CoA reductase inhibitorsLEK PHARMACEUTICALS·Filed 2007·Application pending·0 cites
- 2960US2011008439A1Duloxetin compositionLEK PHARMACEUTICALS·Filed 2007·Application pending·0 cites
- 3060US2009264497A1Stable pharmaceutical formulation comprising a hmg-coa reductase inhibitorLEK PHARMACEUTICALS·Filed 2008·Application pending·0 cites
- 3159US6695969B1Process for obtaining HMG-CoA reductase inhibitors of high purityLEK PHARMACEUTICALS·Filed 1999·Granted Feb 24, 2004·18 cites·26 claims
- 3257US7534870B2Stable pharmaceutical composition comprising erythropoietinLEK PHARMACEUTICALS·Filed 2003·Granted May 19, 2009·3 cites·18 claims
- 3356US9622976B2Pharmaceutical compositionLEK PHARMACEUTICALS·Filed 2014·Granted Apr 18, 2017·0 cites·7 claims
- 3456US2011112160A1Tablet comprising eprosartan mesylateLEK PHARMACEUTICALS·Filed 2009·Application pending·0 cites
- 3556US2008299193A1Pharmaceutical composition comprising eszopliconeLEK PHARMACEUTICALS·Filed 2008·Application pending·0 cites
- 3656US2023137216A1Stabilization of Pharmaceutical Compositions Comprising PolysorbateLEK PHARMACEUTICALS·Filed 2021·Application pending·0 cites
- 3755US9907757B2Coated particles and pharmaceutical dosage formsLEK PHARMACEUTICALS·Filed 2015·Granted Mar 6, 2018·0 cites·8 claims
- 3855US2011068497A1Preparation of nanoparticles by using a vibrating nozzle deviceLEK PHARMACEUTICALS·Filed 2009·Application pending·0 cites
- 3954US8044086B2Oxidative degradation products of atorvastatin calciumLEK PHARMACEUTICALS·Filed 2005·Granted Oct 25, 2011·0 cites·3 claims
- 4054US7875723B2S-omeprazole magnesiumLEK PHARMACEUTICALS·Filed 2009·Granted Jan 25, 2011·0 cites·10 claims
- 4154US7671215B2Process for the preparation of compounds having an ace inhibitory actionLEK PHARMACEUTICALS·Filed 2004·Granted Mar 2, 2010·1 cites·6 claims
- 4254US6509479B1Process for the removal of a silyloxy protecting group from 4-silyloxy-tetrahydro-pyran-2-onesLEK PHARMACEUTICALS·Filed 2000·Granted Jan 21, 2003·1 cites·13 claims
- 4354US2011262497A1Novel ezetimibe formulationsLEK PHARMACEUTICALS·Filed 2009·Application pending·0 cites
- 4454US2010305087A1Active pharmaceutical ingredient on a solid support, amorphous and with an improved solubilityLEK PHARMACEUTICALS·Filed 2008·Application pending·0 cites
- 4553US10323056B2Crystalline hydrates of 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzeneLEK PHARMACEUTICALS·Filed 2014·Granted Jun 18, 2019·0 cites·15 claims
- 4652US9562082B2Production of glycoproteins with low N-glycolylneuraminic acid (Neu5Gc) contentLEK PHARMACEUTICALS·Filed 2014·Granted Feb 7, 2017·0 cites·17 claims
- 4752US7560474B2Derivatives of pyridilethanol (phenylethyl) amines as inhibitors of cholesterol biosynthesis, process for their preparation and pharmaceutical compositions containing themLEK PHARMACEUTICALS·Filed 2003·Granted Jul 14, 2009·2 cites·10 claims
- 4852US7271269B2Preparation of new pharmaceutically suitable salt of losartan and forms thereof with new purification and isolation methodsLEK PHARMACEUTICALS·Filed 2004·Granted Sep 18, 2007·1 cites·5 claims
- 4952US2010120868A1Process For Preparing Solid Dosage Forms of Rosiglitazone MaleateLEK PHARMACEUTICALS·Filed 2009·Application pending·0 cites
- 5051US9428562B2Production of glycoproteins with low N-glycolylneuraminic acid (NEU5GC) contentLEK PHARMACEUTICALS·Filed 2014·Granted Aug 30, 2016·0 cites·14 claims
Showing the top 50 of 100 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when LEK PHARMACEUTICALS files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →